The Comparison of the Effects of Two Botulinum Toxin A Injection Methods, Follow the Pain and Fixed-site Fixed-dose, on Improving the Quality of Life and Headaches in Patients with Chronic Migraine: A Preliminary Randomized Clinical Trial
Journal Title: Turkish Journal of Neurology - Year 2020, Vol 26, Issue 4
Abstract
Objective: Migraine headaches are one of the most common and debilitating diseases. Chronic migraine (CM) is a type of migraine that reduces quality of life and causes disability. Botulinum toxin A (BT-A) was approved in 2010 by the Food and Drug Administration for CM as one of the treatment options. In BT-A treatment, follow the pain (FTP), fixed-site fixed-dose (FSFD) methods, and combined injections are prevalent. This clinical trial aimed to compare the effects of two methods of BT-A injections in patients with CM to determine the method with the fewest complications, the strongest therapeutic effects, and the lowest costs in improving quality of life. Materials and Methods: In this preliminary clinical trial, 40 patients with CM were screened, and after examining the inclusion criteria, 18 patients completed the trial. After a baseline examination and experiencing a 28-day baseline period, they were randomly divided into FSFD and FTP groups. In our study, we used the Quality of Life Questionnaire, the Migraine Daily Note, and Headache Impact Test-6. Results: A total of 17 women and 1 man completed the trial. Severity and rate of headaches and quality of life scores had better changes in the following months with similar trends in both groups without a significant difference. Conclusion: The comparison of the scores showed an improvement in most patients, but there was no significant difference between the FSFD and FTP groups. However, the results indicated a greater response to the treatment and a higher rate of drug use in the FSFD group.
Authors and Affiliations
Hossein Salehi, Mohaddaseh Fekri, Alireza Vakilian, Mohsen Rezaeaian, Hassan Ahmadinia
Keywords
Related Articles
- EP ID EP691586
- DOI 10.4274/tnd.2020.56767
- Views 145
- Downloads 0
A Rare Cause of Spasticity and Microcephaly: Argininemia
Argininemia is an autosomal recessive urea cycle disorder caused by the deficiency of arginase. Our first case presented with psychomotor retardation, difficulty of walking, and progressive tiptoeing. Laboratory investig...
Transient Encephalopathy with A Single Dose of Oral Metronidazole: A Case Report
Metronidazole (MNZ) is an antibacterial agent widely used in the treatment of anaerobic and protozoal infections, easily penetrating the cerebrospinal fluid and central nervous system. MNZ is well-tolerated, but it can a...
Vessel-wall Imaging for Primary Angiitis of Central Nervous System Diagnosis
No summary
A Multifaceted Evaluation of National Off-label Neurology Applications
Objective: Off-label drug use (OLDU) of neurologic diseases is approved by a regulatory authority, the Turkish Medicines and Medical Devices Agency (TMMDA) in Turkey. It was aimed to investigate the most common neurologi...
Quantitative and Qualitative Assessment of Verbal Fluency in Amnestic Mild Cognitive Impairment
Objective: The objective of this research was to compare the verbal fluency skills of patients diagnosed as having amnestic mild cognitive impairment (aMCI) with the participants without neurologic or psychiatric problem...